Skip to main content
SpringerLink
Log in

VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells

  • Conference Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The effects of vasoactive intestinal peptide (VIP) antagonists on breast cancer cells were investigated. (N-stearyl, norleucine17)VIP hybrid ((SN)VIPhyb) inhibited specific 125I-VIP binding to MCF7, SKBR3, T47D ZR75-1 and MDA-MB231 cells with high affinity (IC50 values of 0.03–0.06μM). (SN)VIPhyb,1μM, inhibited the ability of 10nM VIP to cause elevation of cAMP and to increase c-fos mRNA. Micromolar concentrations of (SN)VIPhyb inhibited the proliferation of MDA-MB231 or MCF7 cells using a MTT and clonogenic assay. Using a MTT assay, (SN)VIPhyb enhanced the ability of taxol and doxorubicin to inhibit breast cancer growth. Using nude mice bearing MDA-MB231 xenografts, VIPhyb potentiated the ability of taxol to inhibit proliferation. The results indicate that VIP receptor antagonists increase the ability of chemotherapeutic drugs to kill breast cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Harris H, Morrow M, Norton L: Malignant tumors of the breast. In: Devita Jr. VT, Hellman S, Rosenberg SA (eds) Cancer: Principles & Practice of Oncology, Lippincott-Raven Press, Philadelphia, PA, 1997, pp 1557-1616

    Google Scholar 

  2. Osborne CK: Tamoxifen in the treatment of breast cancer. Drug Therapy 339: 1609-1618, 1998

    Google Scholar 

  3. MacGregor JI, Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50: 151-196, 1997

    Google Scholar 

  4. Dickson RB, Lippman ME: Molecular biology of breast cancer. In: Devita Jr. VT, Hellman S, Rosenberg SA (eds) Cancer: Principles & Practice of Oncology. Lippincott-Raven Press, Philadelphia, PA, 1997, pp 1541-1557

    Google Scholar 

  5. Ram TG, Kokeny KE, Dilts CA, Ethier SP: Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor I in human mammary epithelial cells. J Cell Physiol 163: 589-596, 1995

    Google Scholar 

  6. Chrysogelus SA, Dickson RB: EGF receptor expression, regulation and function in breast cancer. Breast Cancer Res Treat 29: 29-40, 1994

    Google Scholar 

  7. Roberts T: A signal chain of events. Nature 360: 534-535, 1992

    Google Scholar 

  8. Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y: A single autophosphorylation site confers oncogenicity to the neu/erb B-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 13: 3302-3311, 1994

    Google Scholar 

  9. Hynes NE, Stein DF: The biology of erbB-2/neu/her-2 and its role in cancer. Biochem Biophys Acta, 1995

  10. Zia H, Hida T, Jakowlew S, Birrer M, Gozes Y, Reubi JC, Fridkin M, Gozes I, Moody TW: Breast cancer growth is inhibited by VIPhybrid, a synthetic VIP receptor antagonist. Cancer Res 56: 3486-3489, 1996

    Google Scholar 

  11. Said SI, Mutt V: Peptide with broad biological activity: Isolation from the small intestine. Science 69: 1217-1218, 1970

    Google Scholar 

  12. Arimura A: Pituitary adenylate cyclase activating polypeptide (PACAP): Discovery and current status of research. Regul Peptides 37: 287-303, 1992

    Google Scholar 

  13. Moody TW, Zia F, Draoui M, Brenneman DE, Fridkin M, Davidson A, Gozes I: A VIP antagonist inhibits the growth of non-small cell lung cancer. Proc Natl Acad Sci USA 90: 4345-4349, 1993

    Google Scholar 

  14. Luis J, Said SI: Characterization of VIP-and heloderminpreferring receptors on human small cell lung carcinoma cell lines. Peptides 11: 1239-1244, 1990

    Google Scholar 

  15. Ishihara R, Shigemoto R, Mori K, Takahashi K, Nagata S: Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8: 811-819, 1992

    Google Scholar 

  16. Harmar T, Lutz E: Multiple receptors for PACAP and VIP. Trends Pharmacol Sci 15: 97-99, 1993

    Google Scholar 

  17. Pisegna JR, Wank SA: Molecular cloning and functional expression of the pititary adenylate cyclase activating polypeptide type I receptor. Proc Natl Acad Sci USA 90: 6345-6349, 1993

    Google Scholar 

  18. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeberg PH, Journot L: Differential signal transduction by five splice variants of the PACAP receptor. Nature 365: 170-175, 1993

    Google Scholar 

  19. Moody TW, Leyton J, Coelho T, Knight M, Takahashi K, Koh M, Fridkin M, Gozes I: (Stearyl, Norleucine17)VIPhybrid is a potent non-small cell lung cancer VIP receptor antagonist. Life Sci 17: 1657-1666, 1997

    Google Scholar 

  20. Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, Davidson A, Rubinraut S, Fridkin M, Brenneman DE: Superactive lipophilic peptides descriminate multiple VIP receptors. J Pharmacol Exper Therap 273: 161-167, 1995

    Google Scholar 

  21. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regulation 22: 27-55, 1984

    Google Scholar 

  22. Chou J, Chou TC: Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In: Chow OTC, Rideout DC (eds) Synergism and Antagonism of Chemotherapy. Academic Press, San Diego, 1991, pp 223-244

    Google Scholar 

  23. Gressens P, Hill JM, Gozes I, Fridkin M, Brenneman DE: Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362: 155-158, 1993

    Google Scholar 

  24. Wollman Y, Lilling G, Goldstein MN, Fridkin M, Gozes I: Vasoactive intestinal peptide: A growth promoter in neuroblastoma cells. Brain Res 624: 339-341, 1993

    Google Scholar 

  25. Gozes I, Perl O, Giladi E, Davidson A, Ashur-Fabian O, Rubinrat S, Fridkin M: Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuroprotective drug design. Proc Natl Acad Sci USA 96: 4143-4148, 1999

    Google Scholar 

  26. Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M, Brenneman DE: A hybrid antagonist to vasoactive intestinal peptide: Effects on cellular function in the central nervous system. J Pharm Exp Ther 257: 959-966, 1991

    Google Scholar 

  27. Gespach C, Bawab W, Decremoux P, Calvo F: Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res 48: 5079-5083, 1988

    Google Scholar 

  28. Reubi JC: In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging. J Nucl Med 36: 1846-1853, 1995

    Google Scholar 

  29. Leyton J, Gozes Y, Pisegna J, Coy D, Purdom S, Casibang M, Zia F, Moody TW: PACAP(6-38) is a PACAP receptor antagonist for breast cancer cells. Breast Cancer Res Treat 56: 177-186, 1999

    Google Scholar 

  30. Couveneau A, Rouyer-Fessard C, Maoret JJ, Gaudin P, Nicole P, LaBurthe M: J Biol Chem 271: 12795-12800, 1996

    Google Scholar 

  31. LaBurthe M, Couvineau A, Gaudin P, Maoret JJ, Rouyer-Fessard C, Nicole P. In: Arimura A, Said SI (eds) VIP, PACAP and Related Peptides. Vol 805. Ann NY Acad Sci 1997, pp 94-111

  32. Whitmarsh AJ, Davies RJ: Transcription factor AP-1 regulation by mitogen-activated prote in kinase signal transduction pathways. J Mol Med 74: 589-607, 1996

    Google Scholar 

  33. Ashur-Fabian O, Giladi E, Brenneman DE, Gozes I: Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. Mol Neurosci 9: 211-222, 1997

    Google Scholar 

  34. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and reresents a novel c-Raf-1 signal transduction pathway. Cancer Res 56: 1851-1854, 1996

    Google Scholar 

  35. Koh SW: Modulation of a 190-kD microtublule associated protein in pigment epithelium by VIP. Peptides 10: 1089-1099, 1989

    Google Scholar 

  36. Mendelsohn J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3(12Pt2): 2703-2707, 1997

    Google Scholar 

  37. Ciardiello F, Bianco R, Damiano V, DeLorenzo S, Pepe S, De-Placido S, Fan Z, Mendelsohn J, Raffaele Bianco, Tortora G: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5: 909-916, 1999

    Google Scholar 

  38. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga J, Tripathy D, Baly D, Baugham SA, Twaddel T, Glaspy JA, Slamon DJ: Phase II study of receptor enhanced sensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671;Semin Oncol. 26: 78-83

  39. Mendelsohn J, Fan Z: Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89: 1505-1515, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cell and Cancer Biology Department, Medicine Branch, National Cancer Institute, Rockville, MD, USA

    Terry W. Moody & Julius Leyton

  2. University Colorado Cancer Centre, Denver, CO, USA

    Daniel Chan

  3. Unit on Neurochemistry, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, Bethesda, MD, USA

    Douglas C. Brenneman

  4. Department of Organic Chemistry, Weizmann Institute of Science, Rehovot, Israel

    Mati Fridkin

  5. Department of Clinical Biochemisty, Sackler School of Medicine, Tel Aviv, Israel

    Edgar Gelber, Albert Levy & Illana Gozes

Authors
  1. Terry W. Moody
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julius Leyton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Douglas C. Brenneman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mati Fridkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Edgar Gelber
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Albert Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Illana Gozes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moody, T.W., Leyton, J., Chan, D. et al. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res Treat 68, 55–64 (2001). https://doi.org/10.1023/A:1017994722130

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1017994722130

Search

Navigation